26.70
+0.11(+0.41%)
Currency In USD
| Previous Close | 26.59 |
| Open | 26.54 |
| Day High | 27.31 |
| Day Low | 26.1 |
| 52-Week High | 30.5 |
| 52-Week Low | 4.17 |
| Volume | 169,366 |
| Average Volume | 320,257 |
| Market Cap | 1.2B |
| PE | -3.87 |
| EPS | -6.9 |
| Moving Average 50 Days | 26.53 |
| Moving Average 200 Days | 17.29 |
| Change | 0.11 |
If you invested $1000 in Septerna, Inc. (SEPN) since IPO date, it would be worth $1,247.66 as of February 10, 2026 at a share price of $26.7. Whereas If you bought $1000 worth of Septerna, Inc. (SEPN) shares 1 year ago, it would be worth $2,027.33 as of February 10, 2026 at a share price of $26.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
4 hours ago
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026,
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the company will pre
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
GlobeNewswire Inc.
Jan 08, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A